Quibim Secures $50M Series A to Advance AI-Powered Medical Imaging Diagnostics
核心洞察
Spanish AI company Quibim (搜索) has raised $50 million in Series A funding to expand its AI-powered medical imaging biomarker platform for disease diagnosis and research applications.
The company's technology, already deployed in 170+ organizations worldwide, includes tools for detecting neurodegenerative diseases (搜索), various cancers, and liver conditions through advanced imaging analysis.
Strategic partnerships with major players like Philips, Merck KGaA, Novartis, and Johnson & Johnson position Quibim (搜索) for significant expansion in the growing AI medical imaging market.
Valencia-based artificial intelligence company Quibim (搜索) has secured $50 million in Series A financing to accelerate the global deployment of its innovative medical imaging biomarker platform. The funding round was led by Asabys and Buenavista, with participation from UI Investments, GoHub Ventures, Amadeus Capital Partners, and other prominent investors.
Advanced AI Solutions for Disease Detection
Quibim (搜索)'s flagship product, QP-Brain, represents a breakthrough in neurological diagnostics by identifying early-stage neurodegenerative diseases (搜索) through sophisticated MRI analysis. The platform detects subtle changes in brain scans that may elude even experienced radiologists, enabling earlier intervention and potentially better patient outcomes.
The company's comprehensive portfolio extends beyond neurology, encompassing diagnostic solutions for prostate, lung, and breast cancers, as well as liver disease (搜索). These tools leverage various imaging modalities, including MRI, PET, and CT scans, while also facilitating the analysis of complex multi-omics datasets for clinical research.
Strategic Industry Partnerships
Quibim (搜索) has established significant partnerships with leading healthcare and pharmaceutical companies. A global collaboration with Philips will integrate Quibim's AI models directly into MRI scanners, enhancing diagnostic capabilities at the point of care. The company has also formed strategic alliances with pharmaceutical giants, including a notable partnership with Merck KGaA to explore biomarkers and radiomics for predicting immunotherapy response in cancer patients.
Innovation in Digital Twin Technology
At the forefront of medical innovation, Quibim (搜索) is developing advanced digital twin technology to create dynamic patient models. These sophisticated simulations aim to enhance patient stratification, improve drug development success rates, and enable pre-treatment testing. The company is also working on whole-body analysis models that combine imaging technologies with computing and AI capabilities.
Market Impact and Future Growth
With its technology already deployed in more than 170 organizations worldwide, Quibim (搜索) is positioned to capitalize on the expanding AI-powered medical imaging market, which is projected to reach $14 billion annually by 2032. The new funding will support international expansion efforts, particularly in the U.S. market, and facilitate continued product development.
"Quibim (搜索)'s mission is to turn imaging into a catalyst for precision health," stated Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim. "Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes."